Lv0
0 积分 2023-09-19 加入
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
14天前
已完结
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
16天前
已完结
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
16天前
已完结
Prospective Evaluation of Taste Function in Patients With Head and Neck Cancer Receiving Intensity-Modulated Radiotherapy
16天前
已完结
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
16天前
已完结
Rethinking mechanisms of neurotoxicity with BCMA directed therapy
16天前
已完结
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
17天前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
17天前
已完结
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations
20天前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
22天前
已完结
皖公网安备34019202002308
